Data Published in The Lancet Shows Positive Results at Primary Endpoint in the Treatment of Resistant Hypertension with MobiusHD Device
Publication Follows Positive Interim Results in US and EU Patients Presented at the European Society of Cardiology Conference
MOUNTAIN VIEW, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) -- Vascular Dynamics, Inc. (VDI), a privately held medical device company developing novel solutions for the treatment of hypertension, today announced European results of the company's first-in-human trial of its MobiusHD® implant published in The Lancet. The publication reported an average reduction of 24-hour ambulatory systolic blood pressure of 21 mmHg from baseline in the 30 European patients 6 months after implantation. Moreover, the Study authors reported that implantation of the MobiusHD device was straightforward for experienced interventionists, with a 100 percent procedural success rate.
The Lancet publication, which was posted today online, noted that the CALM-FIM_EUR study was a first-in-human feasibility study in which 30 patients were enrolled at 6 European centers in the Netherlands (5) and Germany (1) between December 2013 and February 2016. All patients had resistant hypertension, defined as office systolic blood pressure above 160 mmHg, despite the use of three or more antihypertensives, including a diuretic. The MobiusHD devices were implanted unilaterally in the internal carotid artery. Mean office blood pressure was 184/109 mmHg at baseline and was reduced by 24/12 mm Hg at 6 months. Mean baseline 24-hr ambulatory blood pressure was 166/100 mmHg at baseline and was reduced by 21/12 mmHg at 6 months despite an observed reduction in hypertensive medication. The investigators reported 6 serious adverse events, all of which were reported to have resolved without sequelae.
"These published results of the CALM-FIM_EUR study demonstrate that the MobiusHD device may significantly reduce both office and ambulatory blood pressure among patients on three or more drugs who have been unable to control their hypertension," said Wilko Spiering, MD, internist-vascular medicine specialist, University Medical Center Utrecht, the Netherlands and President of the Dutch Hypertension Society, lead author of the study. "Our positive experience with the MobiusHD device demonstrates the need for continued investigation in a sham-controlled setting, which is currently running in the Netherlands and is starting up in the United States, United Kingdom, and Germany shortly."
The Lancet publication comes immediately following the presentation of interim results of the CALM-FIM trials (US and EU study data) at a podium session at the 2017 Annual Congress of the European Society of Cardiology in Barcelona by Dr. Spiering.
"These results present a potentially significant advance in the treatment of hypertension, particularly with regard to those patients whose blood pressure has remained uncontrolled despite lifestyle changes and multi-drug therapy," said Dr. Bryan Williams, co-Principal Investigator of the CALM 2 trial from University College London (UCL) Institute of Cardiovascular Science and National Institute for Health Research UCL Hospitals Biomedical Research Centre. He is also Chairman of the European Council on Hypertension of the European Society of Cardiology. "We hope that continued study in the upcoming CALM 2 trial will continue to garner the results we've seen thus far, which will provide an important addition to our approach to controlling this incredibly pernicious and deadly disease."
The MobiusHD System, a minimally-invasive system, capitalizes on the ability of the body's baroreceptor mechanism to regulate blood pressure. Baroreceptors are receptors located in the carotid artery that sense blood pressure and relay that information to the brain. The MobiusHD implant is designed to amplify the signals received by the surrounding arterial baroreceptors, and thereby increase the body's natural response to lower blood pressure through vasodilation.
"The benefit of a minimally invasive therapy that can reduce ambulatory blood pressure significantly in these truly resistant patients, including those that have failed renal denervation, has always been our goal," said Robert Stern, president and CEO of Vascular Dynamics Inc. "With these positive results, we will now press on to gather the sham randomized controlled data to ensure that the MobiusHD can impact patient care positively."
About Resistant Hypertension
Hypertension, or elevated blood pressure, is a common medical condition that currently affects one billion people worldwide.1 If left untreated, hypertension can cause life-threatening problems, including heart attack, aneurysm, stroke or kidney failure. Patients with hypertension can often reduce their risk factors by making lifestyle changes such as losing weight, quitting smoking, and increased exercise. In cases with advanced hypertension, medical therapies may be prescribed. Resistant hypertension cannot be controlled with medical therapies. Patients experiencing resistant hypertension are at four times greater risk of cardiovascular events compared with hypertensive patients achieving blood pressure targets.2 The American Heart Association (AHA) estimates that high blood pressure costs the U.S. $46 billion each year, including the cost of healthcare services, medications to treat high blood pressure, and lost productivity.
About Vascular Dynamics, Inc.
Vascular Dynamics develops catheter-delivered technologies to bring a better quality of life to patients who are resistant to conventional treatments for hypertension. The device is covered by ten issued and pending U.S. and international patents. The MobiusHD system has received a CE Mark for the treatment of hypertension in the European Union. However, the MobiusHD system is not commercially available in the United States. More information is available at www.vasculardynamics.com.
CAUTION: In the United States, the MobiusHD Device is limited by law to investigational use only.
1 Kearney PM, et al. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365(9455):217-23
2 Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18: 1422-8.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Vascular Dynamics, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Euro Manganese Inc. Closes Plant Site Option Agreement and Provides Operational Update17.10.2018 22:58 | Pressemelding
VANCOUVER, British Columbia, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V/ASX: EMN) (“EMN” or the "Company") announced today that it has waived the conditions precedent to the closing of an Option Agreement to acquire EP Chvaletice s.r.o. (“EPCS”), a Czech operating company whose principal asset is a large parcel of industrial zoned land adjacent to the Chvaletice Manganese Project, where EMN proposes to develop its high-purity manganese processing facility. In addition, EMN is pleased to provide an operational update for its Chvaletice Manganese Project. Due Diligence Completed and First Payment made on EPCS Option Agreement Following the satisfactory completion of an environmental, financial and legal due diligence review, the Company reports that it has made the first instalment of 14 million Czech Korunas (approx. CAD$815,000) related to an option agreement dated August 13, 2018 giving it the right to acquire a 100% interest in EPCS (the “Option Agreement”). EPCS is
Constellation Brands Names Bill Newlands Next CEO17.10.2018 22:55 | Pressemelding
Newlands to Succeed Rob Sands Effective March 1, 2019; Sands to Become Executive Chair VICTOR, N.Y., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, today announced Bill Newlands will assume the role of president and chief executive officer (CEO), succeeding current CEO Rob Sands, on March 1, 2019. Also effective March 1, 2019, Rob Sands will assume the role of executive chair. Richard Sands, who is currently serving in the role of executive chair, will assume the role of executive vice chair on March 1, 2019. “Since joining Constellation Brands in 2015, Bill has made a significant impact on our company, finding ways to leverage our unique capabilities as a leading total beverage alcohol provider to meet consumers’ evolving needs and accelerate growth,” said Constellation Brands’ CEO Rob Sands. “Bill understands what it takes to succeed in this rapidly evolving market and he’s the right person to lead our company g
Elite Capital & Gas broadens financial services and signs a deal with Tabarak Investment Capital Limited17.10.2018 16:30 | Pressemelding
DUBAI, United Arab Emirates, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Today the President of Elite Petro & Gas, Mr. George Matharu and the President of Tabarak Investment Capital Limited (Investment Bank), Dr. Mohamed Ahmadi announced a deal in which the two companies will use their combined resources to execute physical commodity trades, and provide banking and finance facilities for oil and gas transactions. The alliance between the two entities will also allow compliance related activities to be carried out from two major international hubs of London and Dubai. This increases the international presence of both companies. Additionally, Elite Petro & Gas (“EPG”) has recently formed relationships with the owners of a number of high profile European, South American and Chinese projects, which EPG and Tabarak can work on together. Tabarak Investment Capital Limited is a regulated investment bank by Dubai Financial Services Authority and incorporated in the Dubai International Financial Centre.
MASH ANNOUNCES EUR 50M EQUITY ROUND AND LAUNCH OF EUROPE'S FIRST STO17.10.2018 15:14 | Pressemelding
Mash Group, a ten year old digital lender and pay later solution provider, announced a EUR 50M equity round and the launch of a Security Token Offering (STO) Helsinki, 17th October: Mash Group Plc, a Finnish FinTech company specializing in consumer lending and pay later solutions, today announced that pre-registration has begun for a Securitized Token Offering (STO). Mash is partnering with DLA Piper, Trust and Tokeny to offer professional investors the means to participate in the current equity round using both crypto and fiat currency. Deloitte has been selected to provide AML and KYC services. The whitelisting process will begin in October with the round closing in December 2018. The STO is part of Mash’s broader EUR 50 million equity round. Security tokens are not the same as utility tokens, as have been issued in a number of recent initial coin offerings (ICOs). The Mash security tokens are backed by assets and token holders would have voting rights and dividend rights of the comp
Meizu officially launches its Overseas smartphone17.10.2018 15:13 | Pressemelding
Jakarta, Indonesia, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Meizu officially launches its Overseas smartphone, produced in and to be sold in the Indonesian market, the C9, as well as 4 other fantastic products, including the Flagship Meizu 16th, the upgraded M6T, POP true wireless earphones and EP52 Lite. A photo accompanying this announcement is available at https://i.imgur.com/C4LvxTd.png ( Jakarta, Indonesia October 15th, 2018) -- Meizu is releasing 5 exciting products, including 3 smartphone models, its iconic flagship 16th, M6T, C9, POP and EP52 Lite earphones). Meizu’s product launch event is set for the 15th October 2018 at the Pullman hotel in Jakarta Indonesia, with a great line-up of speakers, including Meizu’s Co-Founder and Overseas President Mr Guo, and overseas Head of Marketing and packed with over 150 of Indonesia’s top media, bloggers and fans, it’s set to be a fantastic event all round. Meizu is releasing five great products and introducing 2 years’ warranty on their smartp
eVestment Launches Market Lens to Arm Asset Managers with Next Level Insights to Win More Institutional Investment Mandates17.10.2018 15:00 | Pressemelding
ATLANTA, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Institutional asset managers looking for the next level of insights in their pursuit of institutional investment mandates can now turn to Market Lens from eVestment, a global leader in institutional investor data and analytics. Market Lens offers a robust feature set including a comprehensive mandate database; investor, consultant and manager profiles; and more than 35,000 documents, audio recordings and videos. These assets include manager presentations, consultant recommendations and research. The new solution also features customized email alerts, saved searches and export capabilities for easy integration into client workflows. The underlying public fund documents allow Market Lens to feature unique investment insights, including product ratings, target asset allocation, actual negotiated fees paid and, leveraging eVestment relationships with institutional investment consultants, undisclosed consultant search data. “In their efforts to win
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom